Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive mCRPC after progression on ARPIs, including patients with and without prior taxane treatment. PSMA-Add was the first phase III trial to target PSMA in mHSPC.

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to results of a drug treatment trial in men whose prostate cancer had returned.

Nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations do not receive PARP inhibitors, a new study finds.

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Johann S. De Bono discussing emerging new therapeutic strategies for advanced prostate cancer.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide and leuprolide,

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen deprivation therapy cuts the risk of death by 40% over 8 years, according to final overall survival results from the phase 3 EMBARK trial.

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic testing in advanced prostate cancer. Dr. Paller started her presentation by defining germline versus somatic mutations:

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate cancer, a randomized trial showed.